The concept of abnormality in medical genetics

Theoretical Medicine and Bioethics

Volumn 20, Issue 6, 1999, Pages 537-561

  Hoedemaekers, Rogeer ^a   Ten Have, Henk ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Abnormality; Disease; Genetic disease; Genetic risk; Genetic screening; Genetic testing; Health; Medical genetics; Normality

Indexed keywords

BOOK; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HEALTH; HUMAN; MEDICAL GENETICS; MEDICAL LITERATURE; NOMENCLATURE; PHENOTYPE; REVIEW;

ANALYTICAL APPROACH; GENETIC DISORDERS; GENETICS AND REPRODUCTION; NORMALITY; STANDARDS; STIGMATIZATION; UNCERTAINTY; VALUES;

ABNORMALITIES; GENETIC DISEASES, INBORN; GENETIC SCREENING; GENETICS, MEDICAL; HEALTH; HUMANS; REFERENCE STANDARDS; RISK ASSESSMENT; SOCIAL VALUES; UNCERTAINTY;

EID: 0033504350     PISSN: 13867415     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009949222667     Document Type: Review

References (61)

1. Fox-Keller E. Master molecules. In: Cranor CF, ed. Are Genes Us? The Social Consequences of the New Genetics, New Brunswick, New Jersey: Rutgers University Press, 1994: 89-98.
2. Lloyd EA. Normality and variation. In: Cranor CF. op. cit.: 99-112.
3. Cranor CF. Genetic causation. In: Cranor CF. op. cit.: 125-141.
4. Fox-Keller E. Nature, nurture and the human genome project. In: Kevles DJ and Leroy Hood, eds. Scientific and Social Issues in the Human Genome Project. Cambridge Mass, and London: Harvard University Press (paper-back), 1993: 281-299.
5. Gelehrter DJ, Collins FS. Principles of Medical Genetics. Baltimore: Williams & Wilkins, 1990.
6. Mueller RF, Young ID. Emery's Elements of Medical Genetics. Edinburgh and London: Churchill Livingstone, 1995.
7. Strachan T, Read AP. Human Molecular Genetics, Oxford: Bios Scientific Publishers, 1996.
8. Andrews LB, et al, eds. Assessing Genetic Risks: Implications for Health and Social Policy. Washington D.C.: Institute of Medicine, National Academy Press, 1994.
9. Nuffield Council on Bioethics. Genetic Screening: Ethical Issues. London: Nuffield Council on Bioethics, 1993.
10. U.S. Congress, Office of Technology Assessment. Cystic Fibrosis and DNA Tests: Implications of Carrier Screening. Washington: U.S. Government Printing Office, 1992.
11. World Health Organisation. Community control of hereditary anaemias: memorandum from a WHO meeting. In: Bulletin of the World Health Organisation 1983; 61: 63-80.
12. We have examined articles written in the period 1975-1995 and published in The New England Journal of Medicine and The Lancet.
13. Davies K, White M. Breakthrough: the Quest to Isolate the Gene for Hereditary Breastcancer. London: Macmillan, 1995.
14. Wilkie T. Perilous knowledge. London/Boston: Faber and Faber, 1994.
15. Ten Have, HAJM. Living with the future: genetic information and human existence. In: Chadwick R, Levitt m, Shickle D, eds. The Right to Know and the Right Not to Know. Aldershot: Avebury, 1997: 87-95.
16. Murphy EA. The normal and the perils of the sylleptic argument. Perspectives in Biolology and Medicine, 1972; 15: 566-582.
17. Vacha J. Biology and the problem of normality. Scientia 1978; 113: 823-846.
18. Ten Have HAJM. Gezondheid in filosofisch perspectief (Health from a philosophical perspective), Filosofie & Praktijk 1987; 8: 113-127.
19. Vacha J. op. cit. (n. 17).
20. Bruhn JG. The diagnosis of normality. Texas Reports on Biology and Medicine 1974; 32: 241-248.
21. See for further discussion of the concepts of health, disease and illness: Hoedemaekers R. and Ten Have HAJM. Genetic health and genetic disease. In: Launis V, Pietarinen J, Räikkä J, eds. Genes and morality: New Essays. Atlanta: Rodopi, 1999: 121-143 and: Hoedemaekers, R. Normative Determinants of Genetic Screening and Testing: An Examination of Values, Concepts and Processes influencing the Moral Debate (diss). Delft: Eburon P & L.
22. See for further discussion of the concepts of health, disease and illness: Hoedemaekers R. and Ten Have HAJM. Genetic health and genetic disease. In: Launis V, Pietarinen J, Räikkä J, eds. Genes and morality: New Essays. Atlanta: Rodopi, 1999: 121-143 and: Hoedemaekers, R. Normative Determinants of Genetic Screening and Testing: An Examination of Values, Concepts and Processes influencing the Moral Debate (diss). Delft: Eburon P & L.
23. Caplan AL. Introduction. In: Caplan AL, Engelhardt HT Jr, McCartney JJ, eds. Concepts of Health and Disease: Interdisciplinary Perspectives. Reading, Massachusetts: Addison-Wesley Publishing Company, 1981: xxiii-xxxi.
24. Engelhardt HT Jr. The concepts of health and disease. In: Caplan AL, Engelhardt HT Jr, McCartney JJ, eds. op. cit.: 31-45.
25. Kass LR. Regarding the end of medicine and the pursuit of health. In: Caplan AL, Engelhardt HT Jr, McCartney JJ, eds. op. cit.: 3-30.
26. Boorse C. Health as a theoretical concept. Philosophy of Science 1977; 44: 542-573.
27. Boorse C. On the distinction between disease and illness. In: Beauchamp TL, Walters L, eds. Contemporary Issues in Bioethics. Belmont, California: Wadsworth Publishing Company, 1982; 64-73.
28. King LS. What is disease? In: Caplan AL, Engelhardt HT Jr, McCartney, JJ, eds. op. cit. (n. 21): 107-118. For further discussion of the distinctions between statistical abnormality, biological normality as deviation from species design and biological abnormality giving a selective (dis)advantage; see for example, Hoedemaekers R. Ten Have HAJM. Genetic health and genetic disease (see n. 21) and Wachbroit R. Normality as a biological concept. Philosophy of Science 1994; 61: 579-591.
29. King LS. What is disease? In: Caplan AL, Engelhardt HT Jr, McCartney, JJ, eds. op. cit. (n. 21): 107-118. For further discussion of the distinctions between statistical abnormality, biological normality as deviation from species design and biological abnormality giving a selective (dis)advantage; see for example, Hoedemaekers R. Ten Have HAJM. Genetic health and genetic disease (see n. 21) and Wachbroit R. Normality as a biological concept. Philosophy of Science 1994; 61: 579-591.
30. Davis PV, Bradley JG. The meaning of normal, Perspectives in Biology and Medicine, 1996; 40: 68-77.
31. Plotz PH. Deconstructing disease: an anatomy of illness in the age of molecular biology. Perspectives in Biology and Medicine 1997; 40: 160-164.
32. The precise role between genetic and environmental factors is still poorly understood and subject of an ongoing debate. See, for example: Editorial. What are genes for? Nature Genetics 1996; 14: 235-236, Judson, HF. The Eight day of Creation, Harmondsworth: Penguin books and Tauber AI, Sakar S, The human genome project: has blind reductionism gone too far? Perspectives in Biology and Medicine 1992; 35: 220-235.
33. The precise role between genetic and environmental factors is still poorly understood and subject of an ongoing debate. See, for example: Editorial. What are genes for? Nature Genetics 1996; 14: 235-236, Judson, HF. The Eight day of Creation, Harmondsworth: Penguin books and Tauber AI, Sakar S, The human genome project: has blind reductionism gone too far? Perspectives in Biology and Medicine 1992; 35: 220-235.
34. The precise role between genetic and environmental factors is still poorly understood and subject of an ongoing debate. See, for example: Editorial. What are genes for? Nature Genetics 1996; 14: 235-236, Judson, HF. The Eight day of Creation, Harmondsworth: Penguin books and Tauber AI, Sakar S, The human genome project: has blind reductionism gone too far? Perspectives in Biology and Medicine 1992; 35: 220-235.
35. Cf. Wachbroit RS, Distinguishing genetic disease and genetic susceptibility. American Journal of Medical Genetics 1994; 53: 236-240. Wachbroit does not clarify what criteria can be used to define an environment as normal or abnormal.
36. Flew A. Disease and mental disease. In: Caplan AL, Engelhardt HT Jr, and McCartney JJ, eds. op. cit. (n. 21): 433-442.
37. Lloyd EA, op. cit. (n. 2).
38. Canguilhem G. The Normal and the Pathological, New York: Zone Books, 1991.
39. Strachan T, Read AP. op. cit. (n. 7).
40. Kahn JP, Genetic harm: bitten by the body that keeps you? Bioethics 1991; 5: 289-308.
41. Engel GL. The need for a new medical model: a challenge for biomedicine. In: Caplan AL, Engelhardt HT Jr, McCartney JJ, eds. op. cit. (n. 21): 589-607.
42. Hoedemaekers R, Ten Have HAJM. Genetic health and genetic disease (see n. 21).
43. Engel GL. The need for a new medical model for biomedicine. In: Caplan Al, Engelhardt HT Jr, McCartney JJ, eds. op. cit. (n. 21): 589-607.
44. Pörn I. Health and adaptedness, Theoretical Medicine 1993; 14: 295-303.
45. Nordenfelt L, On the Nature of Health, 2nd revised and enlarged ed. Dordrecht, Boston, London: Kluwer Academic Publishers, 1995.
46. Schmidt RM, Curran WJ. A national genetic disease program: some issues of implementation. New England Journal of Medicine 1976; 295: 819.
47. Golbus MS, et al. Prenatal diagnosis in 3000 amniocenteses. New England Journal of Medicine, 1979; 300: 159.
48. Antonarakis SE. Diagnosis of genetic disorders at the DNA level. New England Journal of Medicine, 1989; 320: 154.
49. Editorial. Prenatal diagnosis - when and how? New England Journal of Medicine 1992; 327: 636.
50. Editorial. Directive counselling. Lancet 1982; vol ii: 368.
51. Bowling FG, et al. Screening for cystic fibrosis: use of ΔF508 mutation (Letter), Lancet 1990; 335: 926.
52. Editorial. Screening for cystic fibrosis. Lancet 1992; 340: 210.
53. Uzych L. Ethical aspects of predictive testing (Letter), Lancet 1986; vol i: 1445-1446.
54. Lloyd EA (see n. 2).
55. Of course in non-genetic testing in clinical medicine the concept of abnormality is in common use, and this concept is used for deviations from the standard range linked with a slight probability, as well as with greater or absolute certainty that a specific condition will develop. It is also linked with serious as well as non-serious conditions. It should be pointed out, however, that in a patient-doctor relationship these deviations are usually further specified, for example as slightly elevated, slightly abnormal, highly elevated etc., and that further explanations are usually provided with regard to the probability that a specific condition will arise and whether it will be serious or not. Where the possibility of personal communication does not exist or where these explanations are not provided there is reason for more careful use of the concept of abnormality also in clinical medicine. In medical genetics there is even more reason for careful use of the concept of abnormality. Not only because the reference standard is often not clear, but also because its potential for raising anxiety in combination with the term genetic (with - for the layperson - its connotations of inevitability and predetermination) can create greater concern than is necessary. Careful use is especially indicated if test-results are not communicated personally and further counselling is not provided, as for example in written pre-test information or when test-results are provided in writing. Recent reports see this as a real possibility in the (near) future (e.g. Andrews LB et al, see n. 8).
56. University Diagnostics Limited, London, U. K. Cystic Fibrosis. n.d.
57. Hoedemaekers R. Predictive screening and the concept of risk. In: Clarke A, ed. The Genetic Testing of Children, Oxford: Bios Scientific Publishers 1998: 245-264.
58. Lippman A. Led (Astray) by genetic maps: the cartography of the human genome and health care. Social Science and Medicine 1992; 35: 1469-1476.
59. Hadjiminas M. The Cyprus experience - screening to combat a serious genetic disease. In: Ethics and Human Genetics. Proceedings: 2nd Symposium of the Council of Europe on Bioethics, Strasbourg: Council of Europe Press, 1995: 27-48; Hoedemaekers R. Ten Have HAJM. Geneticization: The Cyprus paradigm, The Journal of Medicine and Philosophy 1998; 23: 274-287
60. Hadjiminas M. The Cyprus experience - screening to combat a serious genetic disease. In: Ethics and Human Genetics. Proceedings: 2nd Symposium of the Council of Europe on Bioethics, Strasbourg: Council of Europe Press, 1995: 27- 48; Hoedemaekers R. Ten Have HAJM. Geneticization: The Cyprus paradigm, The Journal of Medicine and Philosophy 1998; 23: 274-287
61. Cystic Fibrosis Trust, Bromley, Kent, UK, n.d.